

Tablica 11.1. Prvih 30 lijekova po financijskoj potrošnji izraženo u kunama u 2022. godini, na teret HZZO-a

RBR	ATK	INN	UKUPNI IZNOS
1	L01XC18	pembrolizumab	370.484.052
2	L01EL01	ibrutinib	164.631.320
3	B01AF01	rivaroksaban	149.935.016
4	V06DX03	namirnice za enteralnu primjenu	130.414.340
5	L01XC32	atezolizumab	126.155.016
6	L02BB04	enzalutamid	123.485.971
7	L01XC17	nivolumab	114.524.234
8	L04AA36	okrelizumab	107.194.637
9	L01XC07	bevacizumab	102.780.551
10	L01XC24	daratumumab	99.220.949
11	N05AX13	paliperidon	96.588.717
12	A02BC02	pantoprazol	93.337.464
13	L04AX04	lenalidomid	91.434.399
14	L01XC13	pertuzumab	90.700.294
15	J07BX03	cjep.prot. COVID-19	90.486.461
16	L01XC03	trastuzumab	85.870.985
17	L04AB04	adalimumab	80.499.293
18	B01AF02	apiksaban	79.466.109
19	B05AA01	albumin, ljudski	79.114.457
20	C10AA05	atorvastatin	73.095.238
21	L01EF02	ribociklib	72.544.172
22	J06BA02	imunoglobulini, humani, za i.v. primjenu	71.439.434
23	C09DX04	valsartan i sakubitril	69.990.230
24	L04AB02	infliksimab	68.154.643
25	C09BX01	perindopril, amlodipin i indapamid	63.528.339
26	A10BJ06	semaglutid	62.669.985
27	L01XC14	trastuzumab emtanzin	60.411.342
28	B05BB01	elektroliti	59.344.269
29	B01AE07	dabigatran eteksilat	58.740.016
30	L01XY02	pertuzumab, trastuzumab	58.187.390